STERIMED acquired by SAGARD
Context
Sterimed, a global leader in medical sterilization packaging, has entered into exclusive negotiations with Sagard to organize a secondary LBO. This transaction facilitates the exit of Meeschaert Capital Partners, which held a majority stake since 2016 following the group's spin-off from ArjoWiggins. The current management team, led by CEO Thibaut Hyvernat, will remain significantly invested in this new chapter.
STERIMED, which reported an EBITDA margin of [members only] in 2018, is valued in this transaction at an EV/EBITDA multiple of [members only], to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
A global leader in the manufacturing of medical sterilization packaging solutions. Sterimed designs, produces, and markets high-performance packaging materials (paper, film, and complex materials) used by medical device manufacturers and hospitals to maintain the sterility of instruments. The group operates several production sites worldwide (France, China, USA, Mexico).
Ent. Value
€100–200M
Equity Value
[members only]
Multiples
EV / Revenue
[members only]
EV / EBITDA
[members only]
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with STERIMED
Other operations with STERIMED
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 02/2020 | PERRIGO COMPANY | HIGH RIDGE BRANDS (ORAL CARE PORTFOLIO) | UNITED STATES | Generics / Labs |
| 10/2019 | DENTRESSANGLE | MARLE GROUP | FRANCE | Implants & Prosthetics |
| 08/2019 | PERMIRA | CAMBREX CORPORATION | UNITED STATES | CDMO |
| 07/2019 | 3I | IONISOS | FRANCE | CDMO |
| 07/2019 | BC PARTNERS | Synthon International | NETHERLANDS | Generics / Labs |
| 07/2019 | PERMIRA | QUOTIENT SCIENCES | UNITED KINGDOM | CDMO |
| 05/2019 | ARDIAN | SINTETICA | SWITZERLAND | Pharma & Biotech |
| 04/2019 | EURAZEO | D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) | NETHERLANDS | Medical Devices |
| 04/2019 | ICG / MERIEUX EQUITY PARTNERS | DOC GENERICI | ITALY | Generics / Labs |
| 12/2018 | MERCK & CO. | ANTELLIQ | FRANCE | Animal Health |
Other operations with SAGARD
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 02/2026 | SAGARD | ESSENCES & PARFUMS | FRANCE | Flavors & Fragrances |
| 01/2026 | SAGARD | QUIPMENT | FRANCE | Healthcare Services |
| 11/2024 | SAGARD | VENPA | ITALY | Equipment Rental |
| 10/2024 | SAGARD | FUTUR MASTER | FRANCE | Supply Chain & Ops |
| 03/2024 | SAGARD | PRIMELIS | FRANCE | Digital Marketing, SEO, SEA, Data Analytics |
| 01/2022 | SAGARD | ADIT (AGENCE POUR LA DIFFUSION DE L'INFORMATION TECHNOLOGIQUE) | FRANCE | Consulting & Audit |
| 01/2021 | SAGARD | NUTRISENS | FRANCE | Nutrition & Dietary Supplements |
| 11/2018 | SAGARD / BPIFRANCE | SABENA TECHNICS | FRANCE | MRO (Maintenance, Repair & Overhaul) |
| 02/2015 | SAGARD | DELICE DES 7 VALLEES | FRANCE | Bakery / Pastry |
| 01/2015 | SAGARD / SOCIETE GENERALE CAPITAL PARTENAIRES / EMZ PARTNERS | SAFIC-ALCAN | FRANCE | Specialty Chemicals |
REFERENCES
Revenue range: €100–200M
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of STERIMED by SAGARD are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Target: sterimed
Acquirer: sagard